Railway Pension Investments Ltd Increases Stock Position in Pfizer Inc. $PFE

Railway Pension Investments Ltd increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1,177.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,148,500 shares of the biopharmaceutical company’s stock after buying an additional 1,058,600 shares during the period. Railway Pension Investments Ltd’s holdings in Pfizer were worth $27,840,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC raised its position in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares in the last quarter. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer during the second quarter worth approximately $29,000. Finally, Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer in the second quarter worth $33,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE opened at $25.76 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a fifty day moving average price of $25.01 and a 200 day moving average price of $24.58. The company has a market cap of $146.46 billion, a P/E ratio of 13.70, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Guggenheim lifted their price target on Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, November 24th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.